Memantine Vipharm

Memantine, the active ingredient in Memantine Vipharm, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is prescribed for the treatment of Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Vipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

- Alzheimer’s disease (mild to moderate): may improve cognitive function and daily living activities. - Alzheimer’s disease (moderate to severe): helps maintain functional abilities and slows symptom progression. - Alzheimer’s disease with behavioral symptoms: can reduce agitation and improve overall patient stability.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Nausea: occasional upset stomach. - Confusion: mild disorientation.

Serious or Rare Side Effects: - Seizures: rare convulsive episodes. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Hallucinations: visual or auditory disturbances. - Mood changes: depression or suicidal thoughts. - Cardiac arrhythmia: irregular heartbeat. - Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for specific risks.

- Renal impairment: adjust dose or monitor renal function. - Hepatic disease: assess liver function before use. - History of seizures: use with caution. - Concomitant CNS depressants: monitor for additive sedation. - Pregnancy and lactation: avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Memantine may interact with other medicines that affect the central nervous system or renal clearance.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - Ketamine: additive NMDA blockade may cause severe CNS effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - Diuretics (e.g., furosemide): can alter renal excretion of memantine. - Proton pump inhibitors: may affect absorption. - Alcohol: enhances sedation and dizziness. - Other NMDA antagonists: monitor for additive side effects.